2. Anti-infection
  3. SARS-CoV
  4. SARS-CoV-2-IN-34

SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

SARS-CoV-2-IN-34 Chemical Structure

SARS-CoV-2-IN-34 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

SARS-CoV-2-IN-34 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection[1].

In Vitro

SARS-CoV-2-IN-34 (0.1-100 μM; 30 min) inhibits infection by PsV of SARS variants on Huh-7 and Caco-2 cells with IC50s values ranging from 0.54 to 10.23 μM and inhibits infection of pseudotyped SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, and bat SARSr-CoV WIV1 with IC50s ranging from 1.30 to 12.02 μM[1].
SARS-CoV-2-IN-34 (0.1-100 μM; 30 min) inhibits the replication of authentic SARS-CoV 2 on Caco-2 cell line with an IC50 value of 8.14 μM and inhibits authentic HCoV-OC43 and HCoV-229E infection in RD cells and Huh-7 cells with IC50s of 6.25 and 9.46 μM, respectively[1].
SARS-CoV-2-IN-34 (0.1-100 μM; 2-4 h) potently inhibits cell-cell fusion mediated by S protein of SARS-CoV-2, SARS-CoV, MERS CoV, HCoV-229E and HCoV-NL63 with IC50s ranging from 1.47 to 5.44 μM[1].
SARS-CoV-2-IN-34 (50 μM; 1 h) inhibits SARS-CoV-2 infection at the early stage of viral entry[1].
SARS-CoV-2-IN-34 (0-2 μM) shows binding effects to S1, RBD and HR with Kd value of 67, 61 and 277 nM, respectively[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SARS-CoV-2-IN-34 Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: Huh-7, Caco-2 and RD cell lines
Concentration: 0-1000 μM
Incubation Time: 12 hours
Result: Showed low on Huh-7, Caco-2 and RD cells with CC50s of ＞800, 692.7 and 274.2 μM, respectively.
In Vivo

SARS-CoV-2-IN-34 (60 and 80 mg/kg; intranasal route 0.5 h pre- or post-challenge with HCoV-OC43 and SARS-CoV-2 Delta) effectively protects mice from infection[1].
SARS-CoV-2-IN-34 (50 mg/kg; i.p. and p.o. once ) shows good oral bioavailability and higher absorption rate under fed conditionsis, it is expected to have potential oral bioavailability[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice with HCoV-OC43 infection[1]
Dosage: 80 mg/kg
Administration: Intranasal route; 80 mg/kg 0.5 h pre- or post-challenge with HCoV-OC43
Result: Significantly decreased relative HCoV-OC43 RNA level of both prevention and treatment group.
Animal Model: hACE2-transgenic C57BL/6 mice with SARS-CoV-2 Delta variant infection[1].
Dosage: 60 mg/kg
Administration: Intranasal route; 60 mg/kg 0.5 h pre- or post-challenge with SARS-CoV-2 Delta
Result: Exhibited prophylactic and therapeutic effect against SARS-CoV-2 Delta infection with intranasally administered.
Molecular Weight

1683.06

Formula

C91H119N13O16S
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SARS-CoV-2-IN-34 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SARS-CoV-2-IN-34SARS-CoVSARS coronaviruscyclicγ-AApeptidelong-actingpseudotyped variantsinfectionHR1RBDInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SARS-CoV-2-IN-34
Cat. No.:
HY-P3492
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.